Journal ArticleDOI
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,Carlton G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Fred K. L. Spijkervet,Michael T. Brennan,Salivary Gland Hypofunction,Xerostomia Section +24 more
Reads0
Chats0
TLDR
There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment.Abstract:
This systematic review aimed to assess the literature for management strategies and economic impact of salivary gland hypofunction and xerostomia induced by cancer therapies and to determine the quality of evidence-based management recommendations. The electronic databases of MEDLINE/PubMed and EMBASE were searched for articles published in English since the 1989 NIH Development Consensus Conference on the Oral Complications of Cancer Therapies until 2008 inclusive. For each article, two independent reviewers extracted information regarding study design, study population, interventions, outcome measures, results, and conclusions. Seventy-two interventional studies met the inclusion criteria. In addition, 49 intensity-modulated radiation therapy (IMRT) studies were included as a management strategy aiming for less salivary gland damage. Management guideline recommendations were drawn up for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. There is evidence that salivary gland hypofunction and xerostomia induced by cancer therapies can be prevented or symptoms be minimized to some degree, depending on the type of cancer treatment. Management guideline recommendations are provided for IMRT, amifostine, muscarinic agonist stimulation, oral mucosal lubricants, acupuncture, and submandibular gland transfer. Fields of sparse literature identified included effects of gustatory and masticatory stimulation, specific oral mucosal lubricant formulas, submandibular gland transfer, acupuncture, hyperbaric oxygen treatment, management strategies in pediatric cancer populations, and the economic consequences of salivary gland hypofunction and xerostomia.read more
Citations
More filters
Journal ArticleDOI
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,C. G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Frederik Spijkervet,Michael T. Brennan +22 more
TL;DR: Salivary gland hypofunction and xerostomia are induced by radiotherapy in the head and neck region depending on the cumulative radiation dose to the gland tissue, and treatment focus should be on optimized/new approaches to further reduce the doses to the parotids.
Journal ArticleDOI
Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers
Arjan Vissink,James B. Mitchell,Bruce J. Baum,Kirsten H. Limesand,Siri Beier Jensen,Philip C. Fox,Linda S. Elting,Johannes A. Langendijk,Robert P. Coppes,Mary E. Reyland +9 more
TL;DR: This review addresses the pathophysiology underlying irradiation damage to salivary gland tissue, the consequences of radiation injury, and issues contributing to the clinical management of salivARY gland hypofunction and xerostomia.
Journal ArticleDOI
Interventions for the management of dry mouth: topical therapies.
TL;DR: There is no strong evidence from this review that any topical therapy is effective for relieving the symptom of dry mouth, and both integrated mouthcare systems and oral reservoir devices show promising results but there is insufficient evidence at present to recommend their use.
Journal ArticleDOI
Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline
Noam Yarom,Noam Yarom,Charles L. Shapiro,Douglas E. Peterson,Catherine Van Poznak,Kari Bohlke,Salvatore L. Ruggiero,Salvatore L. Ruggiero,Cesar A. Migliorati,Aliya Khan,Archie Morrison,Archie Morrison,Holly Anderson,Barbara A. Murphy,Devena E. Alston-Johnson,Rui Amaral Mendes,Beth M. Beadle,Siri Beier Jensen,Deborah P. Saunders +18 more
TL;DR: In this paper, the authors provide guidance regarding best practices in the prevention and management of medication-related osteonecrosis of the jaw (MRONJ) in patients with cancer.
Journal ArticleDOI
Treatment of late sequelae after radiotherapy for head and neck cancer
Primož Strojan,Katherine A. Hutcheson,Avraham Eisbruch,Jonathan J. Beitler,Johannes A. Langendijk,Anne W.M. Lee,June Corry,William M. Mendenhall,Robert Smee,Alessandra Rinaldo,Alfio Ferlito +10 more
TL;DR: The available evidence on the use of different therapeutic strategies to alleviate common late sequelae of RT in head and neck cancer patients is reviewed, with a focus on the critical assessment of the treatment options for xerostomia, dysphagia, mandibular osteoradionecrosis, trismus, and hearing loss.
References
More filters
Journal ArticleDOI
World Workshop on Oral Medicine IV: Process and methodology for systematic review and developing management recommendations. Reference manual for management recommendations writing committees.
TL;DR: Methods for systematic review and developing management recommendations for Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007 are presented.
Journal ArticleDOI
Effects of sucking acidic candies on saliva in unilaterally irradiated pharyngeal cancer patients.
TL;DR: Saliva became significantly more undersaturated with respect to HAp in irradiated patients, and failed to return to baseline values during the post-stimulatory period, which it normally does in healthy individuals, so prevention of dental breakdown in these patients should involve counseling regarding choice of stimulant for dry mouth relief.
Journal ArticleDOI
A Pilot Study of Salix SST (Saliva-stimulating Lozenges) in Post-irradiation Xerostomia
TL;DR: There was a marked and statistically significant improvement in the dryness and general comfort of the mouth, and beneficial effects on eating, sleeping and speech.
Journal ArticleDOI
Assessment of salivary function change in nasopharyngeal carcinoma treated by parotid-sparing radiotherapy.
Wen Shan Liu,Hsiang Chi Kuo,Jin Ching Lin,Mao Chang Su,Jong Kang Lee,Ming Jen Chou,Ming Chih Chou,Huei Lee +7 more
TL;DR: With parotid-sparing radiotherapy for nasopharyngeal carcinoma, gland function can recover significantly 12 months after radiotherapy, and rank-order correlations between LENT/SOMA subjective and objective (analytic) grading scores at 6 to 18 months' follow-up were significant.
Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction.
TL;DR: Results of an ongoing study investigating the effects of pilocarpine on radiation-induced salivary gland dysfunction suggest that parotid function was preserved, but not submandibular/sublingual function.
Related Papers (5)
A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life
Siri Beier Jensen,Anne Marie Lynge Pedersen,Arjan Vissink,Elo Andersen,C. G. Brown,Andrew Davies,J. Dutilh,Janet S. Fulton,Ljiljana Janković,Nilza Nelly Fontana Lopes,A. L. S. Mello,L. V. Muniz,C. A. Murdoch-Kinch,Raj G. Nair,Joel J. Napeñas,A. Nogueira-Rodrigues,Deborah P. Saunders,B. Stirling,I. von Bültzingslöwen,Dianna Weikel,Linda S. Elting,Frederik Spijkervet,Michael T. Brennan +22 more
Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
Christopher M. Nutting,Christopher M. Nutting,James P Morden,Kevin J. Harrington,Kevin J. Harrington,Teresa Guerrero Urbano,Shreerang Bhide,Catharine H. Clark,Elizabeth Miles,Aisha Miah,Kate Newbold,Mary Anne Lagmay Tanay,Fawzi Adab,Sarah Jefferies,Christopher D Scrase,Beng K. Yap,Roger A'Hern,M. Sydenham,M. Emson,Emma Hall +19 more